- Conditions
- Optim Lead Insulation Related Adverse Events
- Interventions
- Not listed
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 245
- States / cities
- Alabaster, Alabama • Fort Payne, Alabama • Gadsden, Alabama + 189 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 10,845
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
- Conditions
- Cystic Fibrosis
- Interventions
- AquADEKs-2, control multivitamin
- Drug · Dietary Supplement
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Aurora, Colorado • Orlando, Florida + 12 more
- Conditions
- Colorectal Cancer
- Interventions
- leucovorin calcium, tegafur-uracil
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 75 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 49
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 35 more
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Cubital Tunnel Syndrome, Nerve Compression, Nerve Injury, Ulnar Neuropathies
- Interventions
- Checkpoint BEST System
- Device
- Lead sponsor
- Checkpoint Surgical Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Stanford, California • Chicago, Illinois • St Louis, Missouri + 2 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Placebo, RSVPreF3 OA vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 26,675 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 54 more
- Conditions
- Thoracic, Colorectal Disorders
- Interventions
- observational study
- Other
- Lead sponsor
- Intuitive Surgical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Baton Rouge, Louisiana • Manhasset, New York • Columbus, Ohio + 1 more
- Conditions
- Nausea, Vomiting
- Interventions
- ginger, placebo
- Dietary Supplement · Other
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 745 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 19
- States / cities
- Mobile, Alabama • Honolulu, Hawaii • Chicago, Illinois + 16 more
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip
- Interventions
- Fasinumab, Placebo
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 21
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
- Conditions
- Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
- Interventions
- Olezarsen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more
- Conditions
- Hemophilia A
- Interventions
- BAY94-9027
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 12 Years · Male only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 7
- States / cities
- Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more
- Conditions
- Cerebral Palsy (CP), Motor Disability, Motor Delay
- Interventions
- Stander Use
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Plecanatide, Matching placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 36
- States / cities
- Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Temozolomide
- Biological · Drug
- Lead sponsor
- Dwight Owen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
- Conditions
- Stress-related Changes in Inflammation
- Interventions
- omega-3 supplementation, Oral omega-3 fish oil placebo
- Dietary Supplement
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Thyroid Cancer
- Interventions
- Irofulven + capecitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Columbus, Ohio
- Conditions
- Tobacco-Related Carcinoma
- Interventions
- Questionnaire Administration, Tobacco Smoking
- Other · Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Clazosentan, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more
- Conditions
- Hypoparathyroidism
- Interventions
- 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 17
- States / cities
- Miami, Florida • Macon, Georgia • Jackson, Mississippi + 14 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Placebo, Selonsertib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
- Conditions
- Migraine
- Interventions
- Ubrogepant 100 mg, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Atezolizumab, Biospecimen Collection, Carboplatin, Lumpectomy, Mastectomy, Paclitaxel
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 9 more
- Conditions
- Hypertriglyceridemia, Cardiovascular Disease
- Interventions
- Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 89
- States / cities
- Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more